Quick answer: Texas requires synchronous documented good faith examinations for initial compounded GLP-1 prescribing, strict Corporate Practice of Medicine enforcement, and PC-MSO entity structure for non-physician investors. APRNs in Texas require a delegation agreement (prescriptive authority agreement) with a delegating physician for Schedule II-V controlled substances and most prescribing.
Texas is the second-largest compounded GLP-1 market and has been a center for both compounded medication innovation and aggressive Medical Board enforcement. The Texas Medical Board (TMB) has issued multiple disciplinary actions against telehealth GLP-1 prescribers in 2025-2026.
The five clinical and regulatory parameters that determine whether a compounded GLP-1 program is defensible under Texas board scrutiny.
Synchronous audio-visual is required for the initial prescription of compounded medications via telehealth in Texas. The TMB has explicitly disqualified async-only GFE for higher-risk prescribing.
No universal in-person requirement for compounded GLP-1, but the TMB expects ongoing documented clinical decision-making, not refill-only authorizations.
503A pharmacies shipping to Texas patients require a Texas State Board of Pharmacy nonresident pharmacy license. 503B outsourcing facilities require separate registration.
APRNs in Texas require a delegation agreement (prescriptive authority agreement) with a delegating physician for Schedule II-V controlled substances and most prescribing. The agreement must be on file with the Texas Medical Board.
Compounded semaglutide is non-scheduled, but Texas has heightened reporting requirements for sterile injectable compounding. Schedule II-V prescribing requires DEA registration and TX-specific controlled substance registration (DPS).
Specific Texas statute and regulatory citations operators should reference when structuring a compliant compounded GLP-1 program.
Establishes the prescriptive authority agreement framework between Texas APRNs and delegating physicians — foundational for NP-staffed GLP-1 programs.
The Texas Medical Board's telemedicine practice standards, including requirements for an established practitioner-patient relationship before prescribing.
Prohibits the corporate practice of medicine in Texas — the underlying statute requiring PC-MSO structure for non-physician investors in clinical operations.
Establishes pharmacy licensure and compounding regulations enforced by the Texas State Board of Pharmacy.
Take the assessment — tell us your specialty + target states and we'll map your gaps and what onboarding looks like for you.
Authoritative Texas regulators with jurisdiction over telehealth compounded GLP-1 programs.
Physician licensure, telemedicine rules, CPOM enforcement
Visit official sitePharmacy licensure including 503A nonresident permits and sterile compounding
Visit official siteAPRN licensure and prescriptive authority agreement registry
Visit official siteRegulatory Information Disclaimer
The telehealth compliance information for Texas presented on this page is provided for general informational purposes only and should not be construed as legal advice. The telehealth regulatory landscape is evolving rapidly, with state legislatures, medical boards, and federal agencies frequently updating rules, guidance, and enforcement priorities. While TrueEval makes every effort to keep this information current and accurate, we cannot guarantee that all details reflect the very latest regulatory changes at the time of your visit.
We strongly recommend consulting with a qualified healthcare attorney or compliance professional before making business decisions based on this information. For the most current regulatory requirements, refer directly to your state medical board and relevant licensing authorities. Last reviewed: February 2026.
Take the assessment — tell us your specialty + target states and we'll map your gaps and what onboarding looks like for you.